poly(ethylene) glycol (SH-PEG) (Sigma-Aldrich Corp. St. Louis, MO) was then assembled onto nanoshell surfaces by combining 1 mM SH-PEG and nanoshells in a ratio of 1.5 µL/mL in DI H2O for 12 h, followed by diafiltration to remove the excess SH-PEG. Particles were then suspended in 10% trehalose solution to create an iso-osmotic solution for injection and concentrated by transverse flow filtration to an extinction of 100 ± 5 OD (@ 800 nm) in order to reduce the infused fluid volume. Nanoshells were fabricated under clean conditions in a Class 100 clean room and passed through a 0.45 µm filter before terminal sterilization.
B. Device Calibration
The laser power used was determined based on pathology images of AuroLase-treated human prostate tissue samples verified to be below the threshold for producing nonspecific tissue damage. Excitation times were determined by the near-IR light absorption characteristic of AuroShell-laden tumors in vivo and limited by the onset of tissue photocoagulation under lengthy excitation. Within this time window, temperatures sufficient to induce hyperthermic cell death were achievable in previous mouse studies. Because these parameters may be specific to the properties of AuroShells and prostate tumor, a more quantitative assessment of dose parameters based on these data alone may be misleading, and a current study is ongoing to develop a quantitative physical model of the AuroLase process that may be more generally applicable to this treatment modality.
C. Patient Treatment
Sixteen men aged 58 to 79 with clinical stage T2a or less prostate cancer, Gleason score of 4+3 or less and a minimum post-ablation follow-up of 12-month endpoints were analyzed. All patients were diagnosed by MR-US fusion biopsy, including both targeted and systematic sampling and had discrete MR-visible lesions without other foci of prostate cancer. Systematic sampling refers to the sextant biopsy scheme for the transrectal approach and the transperineal sampling was performed using a modified Barzel template (all biopsies included a minimum of 12 cores)(3). All patients had a single focus of prostate cancer, with the exception of one patient who had two discrete and separately treated lesions. Complete inclusion and exclusion criteria are listed in the supplementary appendix. Multi-parametric MRI (mpMRI) was obtained using a 3T phased array coil and classified using the Prostate Imaging Reporting and Data System version 2 (PI-RADS v2). GSN mediated laser ablation was performed within 4 months of mpMRI acquisition. Diagnostic mpMRI studies and fusion biopsies were accepted if performed at another institution, however all subsequent studies and biopsies were performed at the Mount Sinai Hospital. Initial patient demographics and lesion characteristics are listed in Table S1 .
Regions of interest (ROIs) corresponding to the lesions detected on prior MR/US fusion biopsy were marked in preparation for GSN mediated laser ablation. ROI selection and prostatic segmentation was performed utilizing DynaCAD software (InVivo, A Philips Healthcare Company, Best Netherlands). An 8 to 10mm margin of ablation around the target lesion(s) was marked while avoiding critical nearby structures (e.g., urethra) ( Figure 5 , manuscript). Stereotactic trocar/laser fiber placement was planned utilizing an in-house generated mock-up of a transperineal stepper overlaid on the ablation and tumor ROIs. To ensure complete coverage of the lesion(s), trocar/laser fiber insertion sites were placed approximately 5 to 7mm apart, considering a 4 to 5mm treatment radius around the optical fiber diffuser ( Figure 5 , manuscript).
Treatment took place in two stages on consecutive days. On treatment day 1, patients received a 7.5 mL/kg intravenous infusion of GSN (4.8mg/mL) through a standard non-bis(2ethylhexyl) phthalate infusion set at a rate of 120 to 600 mL/h. Before treatment on day 2, patients received a saline enema and single dose of Gentamicin 160 mg IVPB. Patients subsequently underwent laser illumination under general anesthesia while positioned in the dorsal lithotomy position. Periprostatic nerve block was performed using 1% lidocaine without epinephrine under transrectal ultrasound guidance via the perineum. The procedure was performed with continuous cooling irrigation via a 16 or 18 French 3-way urinary catheter. In conjunction with a biplanar BK ultrasound 8848 probe, 14-gauge grid (CIVCO 610-977), and an EM-tracked MR/US fusion guidance platform with EM compatible stepper (UroNav, A Philips Healthcare company, Best Netherlands), multiple 14G needle-guided introducers were placed transperineally. Once all introducers were in place, the trocars were removed just prior to the laser catheter being inserted sequentially into each trocar cannula and NIR (810±10 nm) was delivered continuously for 3 minutes at a power level sub-ablative in the absence of GSN. Laser power was delivered via a dual lumen, water-cooled catheter (Nanospectra Biosciences, Inc, Houston, TX), housing either a 10mm optical fiber diffuser (OFD) and power up to 4.5W or an 18mm OFD with power up to 6.5W. Depending on the cranio-caudal dimension of the intended ablation zone, consecutive laser activations took place after withdrawing the laser fiber to allow for adequate coverage of the intended ablation zone The specific withdrawal length was dependent on the length of the fiber used for each treatment. An 8mm withdrawal was used for the 10mm OFD and 12-mm withdrawal for the 18mm OFD. All 3D data were recorded on the MR/US fusion guidance platform ( Figure  S1 ).
To monitor and minimize the risk of tissue damage near critical structures, needle thermocouples were placed near them when the intended ablation zone was in close proximity. This included the urethra, urinary sphincter, and/or rectal wall. As a control treatment, a single 3minute continuous laser excitation with the same laser power was performed at a location contralateral to the target lesion to evaluate whether or not ablation occurred in the absence of GSN.
Patients were discharged on the same day of the procedure after several hours of monitoring and a successful voiding trial. At 48-72 hours post-treatment, subjects underwent mpMRI to evaluate the radiologic treatment response at the planned ablation zone. Post-treatment follow-up was performed at 1, 3, 6 and12 months post-ablation. At each visit, a history and physical were performed to document any potential adverse events; additionally, patients' I-PSS, SHIM score, prostate specific antigen (PSA), and liver function tests were documented. At 3-and 12-months patients underwent repeat mpMRI and MR/US targeted biopsy, along with a 12-core systematic biopsy at 12 months.
Establishment and confirmation of a particle-directed, as opposed to a non-specific, laser dose was a two-step process. First, the 6.3±5.8mg biopsy by mass was taken from the treatment zone to document the presence of nanoshells within each treated tumor, Table S1 . An elemental analysis was performed on each biopsy core using Nuclear Activation Analysis as previously described (4) . Healthy prostate tissue is known to collect a minimal background level of 0.4µg/g of nanoshells (5) . Second, the 48-72-hour post-treatment DCE MRI helped to establish the volume of target tissue damage prior to necrotic reformation. This was compared to the minimal thermal ablation zone generated by the control treatment duplicating the laser dose in each patient and was taken as confirmation that the applied laser dose was specific to tissues containing nanoshells. are excluded, due to they will not be able to undergo gadolinium enhance MRI. o Patients with acute or chronic hepatic dysfunction as evidenced by clinically important (> grade 1) changes in AST, ALT, bilirubin, or albumin, or either ALP or GGT values. o Patients with uncontrolled coagulopathies who are at increased risk of bleeding, or with abnormal PT (INR) or PTT. o Altered mental status preventing consent or answering questions during conduct of the trial will be excluded for safety purposes. o Other medical or surgical conditions, especially involving the cardiac, respiratory, renal or hepatic organ systems that would either be unsafe for the patient, would limit study participation, or that would impede the determination of causality of any adverse events experienced during the conduct of this study.
II. Table S1:
IV. Table S2 : Description of adverse events within 90 days of treatment, graded by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
